Japan Market Research Reports & Industry Analysis

Publications found: 12,947
Sort by:

Japan Diagnostic Testing Market: Forecasts by Market Segment And Supplier Shares by Test

US$ 2,760.00

This report provides an overview of the Japanese diagnostic testing market, including sales and market shares of leading reagent and instrument suppliers, as well as test volume and sales forecasts for the following market segments: Blood Banking Cancer ...

October 2012 58 pages

Japan LNG Demand Forecast 2016

US$ 600.00

... Ton in 2009. “Japan LNG Demand Forecast 2016” report gives comprehensive overview on the following aspect related to LNG market in Japan: Natural Gas Reserves, Production & Consumption. LNG Imports by Country During 2011 & 2012 Existing LNG Procurement Contracts by Country Newly Signed LNG Procurement ...

October 2012 60 pages

Japan Solar Power Sector Analysis

US$ 800.00

... on the location. Japan has been involved in solar power development since the early 1990s when the country installed its first solar power plant. It has ... which has been supported by a change in the policies as well. Japan started concentrating on solar power generation since the early 1990s; in 2011, it added more ...

September 2012 70 pages

Future Horizons in the Japanese Flow Cytometry Market: Supplier Shares, Test Volume and Sales Forecasts by Market Segment

US$ 3,600.00

... with significant market impact during the next five years. Five-year volume and sales forecasts for major flow cytometry tests performed in Japanese hospitals and commercial laboratories. Annual placements and installed base of major flow cytometers. Review of current instrumentation technologies and a ...

August 2012 142 pages

Future Horizons in the Japanese Hemostasis Diagnostics Market: Supplier Shares and Sales Forecasts for 40 Tests by Market Segment

US$ 5,200.00

... trends with significant market impact during the next ten years. Ten-year volume and sales forecasts for 40 hemostasis procedures performed in Japanese hospitals and commercial laboratories, including typical hemostasis daily work loads. Placement estimates for major automated and semi-automated systems. ...

August 2012 402 pages

Future Horizons in the Japanese Microbiology Market: Supplier Shares and Sales Forecasts for 100 Infectious Disease Tests by Market Segment

US$ 6,240.00

... etiology of major infectious diseases and microorganisms. Ten-year test volume and sales forecasts for nearly 80 microbiology tests performed in Japanese hospitals, blood banks and commercial laboratories. Instrumentation technologies and feature comparison of leading analyzers. Sales and market shares of ...

August 2012 976 pages

Future Horizons in the Japanese Nucleic Acid Testing Market: Supplier Shares and Sales Forecasts for 35 Tests and Applications by Market Segment

US$ 6,000.00

Highlights Comprehensive 850-page market segmentation analysis of the Japanese NAT market. Major issues pertaining to the Japanese NAT laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. An ...

August 2012 850 pages

Future Horizons in the Japanese Transfusion Diagnostics Market: Supplier Shares and Sales Forecasts for 40 Typing, Grouping and Screening Tests by Market Segment

US$ 5,440.00

Highlights Comprehensive 426-page market segmentation analysis of the transfusion testing market. Major issues pertaining to the Japanese transfusion testing practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years ...

August 2012 426 pages

Future Horizons in the Japanese Tumor Marker Testing Market: Supplier Shares and Sales Forecasts for 40 Cancer Assays by Market Segment

US$ 5,360.00

... , liver, ovarian, testicular, oral, skin and others. Ten-year test volume and sales forecasts over for 40 tumor marker performed in Japanese hospitals, commercial laboratories and physician offices. Placements and installed base of automated and semi-automated analyzers used for tumor marker testing. ...

August 2012 590 pages

Future Horizons in the Japanese Blood Banking Market: Supplier Shares and Sales Forecasts for 40 Typing, Grouping and Screening Tests by Market Segment

US$ 5,440.00

... . Ten-year volume and sales forecasts for 40 blood typing, grouping and infectious disease screening tests, including NAT procedures performed in Japanese blood banks hospitals and commercial laboratories. Annual placements and installed base estimates for major automated and semi-automated analyzers. ...

August 2012 426 pages

Future Horizons in the Japanese Cancer Diagnostics Market: Supplier Shares and Sales Forecasts for 40 Tumor Markers by Market Segment

US$ 5,360.00

... , liver, ovarian, testicular, oral, skin and others. Ten-year test volume and sales forecasts over for 40 tumor marker performed in Japanese hospitals, commercial laboratories and physician offices. Placements and installed base of automated and semi-automated analyzers used for tumor marker testing. ...

August 2012 590 pages

Future Horizons in the Japanese Immunodiagnostics Market: Supplier Shares and Sales Forecasts

US$ 5,440.00

Future Horizons in the Japanese Immunodiagnostics Market: Supplier Shares and Sales Forecasts for 100 Chemistry, TDM, Endocrine, Cancer, Immunoprotein and Abused Drug Tests by Market Segment This report presents a comprehensive analysis of the Japanese clinical chemistry and immunodiagnostics markets, ...

August 2012 559 pages

Future Horizons in the Japanese Coagulation Testing Market: Supplier Shares and Sales Forecasts for 40 Tests by Market Segment

US$ 5,200.00

... trends with significant market impact during the next ten years. Ten-year volume and sales forecasts for 40 coagulation procedures performed in Japanese hospitals and commercial laboratories, including typical coagulation daily work loads. Placement estimates for major automated and semiautomated systems. ...

August 2012 402 pages

Future Horizons in the Japanese Hematology and Flow Cytometry Market: Supplier Shares and Sales Forecasts for 40 Tests by Market Segment

US$ 6,240.00

... during the next ten years. Five- and ten-year volume and sales forecasts for over 30 hematology and flow cytometry procedures performed in Japanese hospitals and commercial laboratories. Annual placements and installed base estimates for major hematology analyzers and flow cytometers. Review of current ...

August 2012 250 pages

Future Horizons in the Japanese Molecular Diagnostics Market: Supplier Shares and Sales Forecasts for 35 Tests and Applications

US$ 6,000.00

This report presents a comprehensive analysis of the Japanese molecular diagnostics market, including: Major issues pertaining to the Japanese molecular diagnostics laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the ...

August 2012 860 pages

Future Horizons in the Japanese Infectious Disease Testing Market: Supplier Shares and Sales Forecasts for 100 Tests by Market Segment

US$ 6,240.00

... etiology of major infectious diseases and microorganisms. Ten-year test volume and sales forecasts for nearly 80 microbiology tests performed in Japanese hospitals, blood banks and commercial laboratories. Instrumentation technologies and feature comparison of leading analyzers. Sales and market shares of ...

August 2012 976 pages

Analyzing Nuclear Power in Japan

US$ 450.00

... stocks and commodities. The report - Analyzing Nuclear Power in Japan - by Aruvian's R'search, explores the importance of nuclear power in today’s world, with Section One ... Basics of Nuclear Power. The report looks at the basics of the nuclear industry that is, how a plant works, analyzing and understanding ...

August 2012 345 pages

Analyzing the Hair Care Market in Japan

US$ 300.00

... of the hair care market in Japan. The report begins with an analysis of the basics of hair care and then moves on to analyze the hair care industry in Japan. The report analyzes the market segmentation, market share ...

August 2012 60 pages

Analyzing Geothermal Power in Japan

US$ 600.00

... Geothermal Power in Japan in its latest research offering Analyzing Geothermal Power in Japan. The report is a comprehensive coverage of the geothermal industry in the region as well as in Japan. The report begins with an introduction to geothermal power. We analyze ...

August 2012 155 pages

Japanese Infectious Disease Testing Market Forecasts and Supplier Shares (DataPack)

US$ 4,640.00

This report presents comprehensive data for the Japanese infectious disease testing market, including: The 2010-2018 test volume and sales forecasts for nearly 80 infectious diseases performed in Japanese hospitals, blood banks and commercial laboratories. The 2010 sales and market shares ...

July 2012 -

Shionogi - Dolutegravir Can Bring ‘Good Times’ Back to Shionogi!

US$ 140.00

... encouraging and similar outcome from four late stage studies can bring Dolutegravir in forefront of anti-HIV therapy – this is the first ... changing in anti-HIV regime, we expect dolutegravir has potential to cross $2.5b. In this report we have analyzed dolutegravir opportunity in mono-thx and in combination ...

July 2012 5 pages

Eisai, Halaven: Uncertainly Mounts Over 2nd Line Approval!

US$ 90.00

... competitor Ixempra (BMY), competition is mounting and we expect it to reach half of the Eisai’s estimates i.e. ~$1b in best case scenario. Following Halaven, Eisai has three late stage ...

July 2012 4 pages

Mitsubishi Tanabe - Collategene US Marketing Rights – A Bet to Get Trump Card for US!

US$ 90.00

Mitsubishi Tanabe (MT) announcement to acquire US marketing rights of Collategene (preparing PhIII, PAD, Anges) ... (MTP) - but are subject to PhIII outcome of Collategene. A solid data in PhIII will prompt MT to ... analyze that the concept and approach of Collategene carries an attractive ‘high-risk-high-reward ...

July 2012 3 pages

Eisai, Belviq Approval – Implications on Eisai’s Bottom Line is Weak!

US$ 90.00

We continue with our Underperform rating on Eisai following approval of Belviq (lorcaserin, 5 HT 2C agonist, partnered with Arena) in the US. Despite ... (Qnexa has PDUFA date on 26th July 2012; we are expecting approval). Belviq administration is to be discontinued if 5% weight loss is not achieved within 12 ...

June 2012 3 pages

Astellas, Mirabegron PDUFA on 29th – Doubts Prevail Over Favorable Outcome!

US$ 90.00

We are skeptical if the FDA will approve Mirabegron (first in class β3-AR agonist, overactive bladder ... the fact that CV risk concerns raised with Mirabegron are mild in nature and the FDA’s ... seems to be more common view of street - we expect mirabegron to generate $300m revenue by 2016 from USA; our WW peak ...

June 2012 3 pages

2012 Japan Blood Banking Market Strategic Analysis: Supplier Shares and Sales Forecasts for 40 Typing, Grouping and Screening Tests

US$ 5,440.00

... a comprehensive analysis of the Japanese blood banking market, including: Major issues pertaining to the Japanese blood banking practice, as well as key economic, ... . Ten-year reagent and instrument sales forecasts. Sales and market shares of leading reagent and instrument suppliers. Review of current and ...

June 2012 426 pages

2012 Japan Coagulation Testing Market Strategic Analysis: Supplier Shares and Sales Forecasts for 40 Tests

US$ 5,200.00

Thisreport presents a comprehensive analysis of the Japanese coagulation market, including: Major issues pertaining to the Japanese coagulation laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. ...

June 2012 402 pages

2012 Japan Strategic Analysis of the Coagulation Testing Market: Forecasts and Supplier Shares

US$ 2,320.00

... Sales and market shares of major instrument and reagent suppliers. Competitive Assessments Extensive strategic profiles of major suppliers and emerging market entrants. Market Segmentation Analysis Hospitals Commercial/Private Laboratories Current and Emerging Products Review of over 40 established ...

June 2012 380 pages

Dainippon Sumitomo - R&D Day Turns ‘Latuda Day’ – Signals Timely sNDA Filing For Bio-Polar Disorder!

US$ 90.00

Dainippon Sumitomo Pharma (DSP) has help R&D day recently and kew take away was that Latuda (lurasidone) ...

June 2012 2 pages

ASTELLAS - Enzalutamide Filed in the US - A ‘Priority Review’ is Likely!

US$ 90.00

... review will be due within 60 days from the filing date, i.e. May 23rd. Enzalutamide is the first in class androgen receptor signaling inhibitor ... data is better for enzalutamide - 4.8 months vs. 3.9 months for Zytiga. Despite enzalutamide’s solid data, we find a limited bottom line impact on Astellas due to its ...

May 2012 3 pages

MITSUBISHI TANABE: Multiple Catalysts Warrant Short Term Correction Opportunity - Offer Good Entry Point!

US$ 140.00

... expected to unfold favorably for Mitsubishi Tanabe (MT) - 1) Upcoming Catalysts From Diabetes Franchise: Canagliflozin is showing promise of better safety and ... our talk with MT. Launch of MT’s teneligliptin, though it will be fifth DPP-4 in Japan, it will have its share backed by two of the strongest marketing ...

May 2012 4 pages

Analyzing the Semiconductors Industry in Japan

US$ 400.00

... costs and local demand. Aruvians Rsearch analyzes the semiconductors industry in Japan in its research presentation Analyzing the Semiconductors Industry in Japan. The report is a comprehensive coverage of the ...

May 2012 105 pages

DAIICHI SANKYO – Acquiring Xinshengyuan – A Little Step Forward in China Aims at Multiple Objectives!

US$ 90.00

Daiichi Sankyo’s (DS) announcement to take over Shanghai Xinshengyuan Pharmaceutical Group in China thru its Chinese subsidiary Daiichi Sankyo (China) Holdings Co., Ltd. came as a surprise last week. Xinshengyuan is largely ...

April 2012 2 pages

DAINIPPON SUMITOMO– PREVAIL TRIAL DATA: Latuda Will Pave A Way For Bipolar Disorder As Well!

US$ 90.00

Top line data from PREVAIL I & II trials announced on 24 April, 2012, show Latuda (lurasidone, already approved for ... line data suggests that safety was found to be consistence in all trials and in acceptable range. This report analysis key findings from PREVAIL I & II studies ...

April 2012 3 pages

TAKEDA - Azilva in Japan - Differentiating Will Not Be Easy!

US$ 90.00

... me-too ARB Azilva (Azilsartan) in Japan in May-12; Azilva aims to retain revenue of Takeda’s best selling ARB Blopress that is soon going off patent. Takeda highlights the ...

April 2012 2 pages

2012 Japan Hematology and Flow Cytometry Market Outlook: Growth Opportunities and Strategies

US$ 6,239.20

This report presents a comprehensive analysis of the Japanese hematology and flow cytometry markets, including: Major issues pertaining to the Japanese blood ... ten-year volume and sales forecasts for over 30 hematology and flow cytometry procedures performed in Japanese hospitals and commercial laboratories. ...

April 2012 250 pages

2012 Japan Hemostasis Diagnostics Market Outlook: Growth Opportunities and Strategies

US$ 5,200.00

... -year reagent and instrument sales forecasts. Sales and market shares of leading reagent and instrument suppliers. Review of hemostasis technologies and their potential market applications. Major opportunities for coagulation instruments and consumables. Profiles of major current and emerging suppliers, ...

April 2012 402 pages

2012 Japan Infectious Disease Testing Market Outlook: Growth Opportunities and Strategies

US$ 6,240.00

This report presents a comprehensive analysis of the Japanese infectious disease testing market, including: Major issues pertaining to the Japanese laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. ...

April 2012 976 pages

2012 Japan Flow Cytometry Market Outlook: Growth Opportunities and Strategies

US$ 3,600.00

... a comprehensive analysis of the Japanese flow cytometry market, including: Major issues pertaining to the Japanese flow cytometry practice, as well as key economic ... . Five-year reagent and instrument sales forecasts. Sales and market shares of leading reagent and instrument suppliers. Review of current and ...

April 2012 142 pages

APRIL-12 REFORMS – New Incentive System Pierces The Ice - GP’s Turn Soft Towards Generics!

US$ 140.00

... Chouzai (leading drug chain in Japan), which suggests that 25% of Rx received from general practitioners (GP’s) contained generic names. From April, 2012, a two-point ... amongst several other regulatory changes and we expect the revised incentive system for GPs will have ~similar magnitude of impact on other ...

April 2012 5 pages

2012 Japan Clinical Chemistry and Immunodiagnostics Market Outlook: Growth Opportunities and Strategies

US$ 5,440.00

... and immunodiagnostics markets, including: Major issues pertaining to the Japanese clinical chemistry and immunodiagnostic laboratory practice, as well as key economic, regulatory ... ten-year volume and sales forecasts for over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays ...

April 2012 559 pages

2012 Japan Cancer Diagnostics Market Outlook: Growth Opportunities and Strategies

US$ 5,360.00

This report presents a comprehensive analysis of the Japanese cancer diagnostics market, including: Major issues pertaining to the Japanese laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. ...

April 2012 590 pages

Japan LNG Markets to 2020 - Analysis and Forecasts of Terminal wise Capacity and Associated Contracts, LNG Trade movements and Prices

US$ 1,999.00

The new comprehensive report on Japan LNG industry from LNGReports provides complete analysis, data and forecasts of the industry from 2000 to 2020. Annual information on LNG trade, capacity, exports/...

April 2012 140 pages

Analyzing Japan’s Steel Industry

US$ 350.00

In 2008, Japan’s domestic steel demand from manufacturers continued at a ... on this highly lucrative industry, bringing you – Analyzing Japan’s Steel Industry. The report is a complete guide to all ... structure, competition in the industry, where the Japanese Steel Industry stands on a global scenario, and much ...

April 2012 80 pages

APRIL-12 REFORMS - NEW ELEMENTS READY TO PROPEL GENERICS UPTAKE WHILE MOLLIFYING INNOVATION

US$ 400.00

New NHI price cuts and a number of structural reforms will be effective from April 1, 2012. Overall, we find them encouraging generics growth to a new level ... we have discuss the impact of price cuts and reforms on Japanese pharma companies, MNCs operating in Japan and Generic companies. We have also discussed ...

March 2012 8 pages

The 2012 Japanese Coagulation Market

US$ 5,200.00

This report presents a comprehensive analysis of the Japanese coagulation market, including: Major issues pertaining to the Japanese coagulation laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. ...

March 2012 402 pages

The 2012 Japanese Infectious Disease Testing Market

US$ 6,240.00

This report presents a comprehensive analysis of the Japanese infectious disease testing market, including: Major issues pertaining to the Japanese laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years. ...

March 2012 976 pages

The 2012 Italian Molecular Diagnostics Market

US$ 4,720.00

... presents a comprehensive analysis of the Italian molecular diagnostics market, including: Major issues pertaining to the Italian molecular diagnostics laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten ...

March 2012 850 pages

The 2012 Japanese Molecular Diagnostics Market

US$ 6,000.00

... presents a comprehensive analysis of the Japanese molecular diagnostics market, including: Major issues pertaining to the Japanese molecular diagnostics laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten ...

March 2012 860 pages

CHUGAI - Hefty Price Cut on Actemra Owing to Exceeding Projected Sales - Slightly Negative!

US$ 90.00

... is expected to be slightly negative. Apart from this, the overall impact of price cuts on Chugai is expected to be at par with industry i.e. ~6%. The reason for this ... NIH price of new drugs. Actemra has been very successful in RA since its launch in Japan in 2008 and remains a key growth driver for Chugai.

March 2012 3 pages

Filters

Search

Categories

1,017
782
660
515
506
370
351
344
344
329
307
259
237
226
184
157
155
149
143
109
95
77
73
71
71
63
61
60
60
56
50
40
31
24
23
22
20
20
19
17
11
11
11
9
8
8
6
6
5
5
5
5
5
5
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
9
3
4
1
1
1
1
1
1
2
1
6
1
2
2
2
2
1
1
1
1
1
1
1
1
1
9
1
71
40
15
15
14
12
10
10
10
9
9
9
9
8
8
7
7
7
6
6
6
6
5
5
5
5
4
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
3
1
2
3
1
1
3
3
1
1
2
2
1
4
1
1
1
1
1
20
5
2
4
1
5
2
2
2
3
2
1
1
1
2
2
2
5
1
2
1
3
3
3
2
3
1
1
68
2
6
1
8
4
1
2
3
4
2
1
1
3
1
2
4
9
304
5
1
374
64
1
2
3
1
1
1
3
1
2
3
4
6
7
3
4
11
2
2
2
2
2
4
5
7
4
1
2
1
1
2
4
4
2
1
3
3
2
1
1,497
1
4
2
1
7
2
1
1
1
2
2
1
1
43
1
3
3
1
6
1
42
5
48
4
2
9
7
12
4
3
3
2
1
15
2
2
10
6
5
3
1
8
2
7
1
34
806
53
3
56
36
28
7
179
5
7

Publishers

4,082
3,654
291
66
64
39
37
14
1
78
258
10
1,339
3
54
1
1
1
46
350
1
1
2
4
34
1
1
1
12
1
38
64
6
3
2
640
4
7
6
1
13
3
1
275
2
1
2
14
1
20
4
64
1,245
16
11
4
4
1
42
3
1

Regions

12,947

Price

Date

Pages

Offers

1
1